{"entity":{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of VBC103 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","summary":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07299747 by VelaVigo Bio Inc, with 255 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12-01. Interventions recorded: VBC103.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07299747","url":"https://clinicaltrials.gov/study/NCT07299747"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07299747","phase":"1/2","setting":"A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors","sponsor":"VelaVigo Bio Inc","enrolled":255,"outcomes":[]},"route":"/trials/nct07299747/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}